Systemic administration of a therapeutic preparation
AssigneeAstraZeneca AB
InventorsKjell Goran Erik Backstrom, Carl Magnus Olof Dahlback, Peter Edman, Ann Charlotte Birgit Johansson
Life of this patent
Estimating the term…
Abstract
A method of treating a patient in need of insulin treatment, including the steps of introducing into the lower respiratory tract of the patient an effective amount of a therapeutic preparation in the form of a dry powder containing (a) insulin and (b) an enhancer compound which enhances the absorption of insulin in the lungs of the patient.
Claims39
A method of treating a patient in need of insulin treatment, comprising introducing into the lower respiratory tract of said patient an effective amount of active compounds (a) insulin and (b) a bile salt which enhances the absorption of insulin in the lower respiratory tract of said patient, which active compounds are comprised in a dry powder suitable for inhalation.
A method of treating a patient in need of insulin treatment, comprising introducing into the lower repiratory tract of the patient a dry powder pharmaceutical preparation comprising active compounds (a) insulin and (b) a bile salt which enhances the systemic absorption of insulin in the lower respiratory tract of said patient, said preparation being in the form of a dry powder in which at least 50% of the total mass of active compounds consists of particles having a diameter of about 10 microns or less, wherein the plasma pharmacokinetics of said insulin delivered by said method more closely resemble the plasma pharmacokinetics of endogenous insulin secreted by a healthy individual in response to a glucose challenge, than do the plasma pharmacokinetics of human insulin delivered by subcutaneous injection.
A method of treating a patient in need of insulin treatment, comprising introducing into the lower respiratory tract of said patient an effective amount of active compounds (a) insulin and (b) a substance which enhances the absorption of insulin in the lower respiratory tract of said patient, which active compounds are comprised in a dry powder suitable for inhalation, provided that said substance is selected from the group consisting of a C8-C16 fatty acid, a salt of such a fatty acid, a salt of glycyrrhizine acid, an acyl carnitine, a phospholipid, and an alkyl saccharide.
Dependencies are inferred from the claim text.